Dr. Wandall is co-director of the Center for Glycobiology at the University of Copenhagen. He is a leader in the study of O-glycoproteomics, defining the location of O-glycans in the human proteome and using this information for genetic dissection of glycan functions in epithelial formation, transformation, and carcinogenesis. In cancer, Dr. Wandall’s work focuses on exploiting cancer-associated glycan changes in detecting cancer at an early stage and for the specific targeting of cancer cells with immunotherapies.
Dr. Wandall earned his M.D. and Ph.D. from the University of Copenhagen. Dr. Wandall has a broad experience in medicine, cancer-biology, glycobiology, immunology. This includes translational work from Harvard Medical School (Research Fellow in Medicine) and roles within biotech where he served as Director, leading and coordinating clinical trial activities. Also, Dr. Wandall is knowledgeable in managing large research projects with industrial partners. He holds several patents and has published more than 100 peer-reviewed articles in journals, including Nature Medicine, Nature Biotech, Nature Immunology, Nature Protocols, Nature Methods, Developmental Cell, PNAS, Dev Cell, Blood, and Cancer Research.